Latest News
OncoTracker Acquires Multiple Myeloma Intellectual Property to Expand Diagnostic Testing
Thursday 14 March 2019

14 March 2019 - California, US-based oncology company OncoTracker, Inc. has agreed to acquire Myeloma and Bone Cancer Research rights to the intellectual property for diagnostic testing of patients with myeloma and bone cancer, the company said.

Terms of the transaction were not disclosed.

OncoTracker said the acquisition of two patents offer clinical utility for multiple myeloma patients.

OncoTracker, Inc. has exclusive rights to a novel blood biomarker that is the target of several multiple myeloma therapies in clinical development.

The company utilises this biomarker to monitor the tumor burden and predict the therapeutic outcome of multiple myeloma patients. 
Details
Date Published: 14/03/2019
Target: Myeloma and Bone Cancer Research rights to the intellectual property for diagnostic testing of patients with myeloma and bone cancer
Country: USA
Sector: Biotechnology
Type: Corporate acquisition
Financing:
Status: Agreed
Vendor:
Buyer: OncoTracker
Comment:
Terms of the deal were not disclosed

Options